Jun 11 |
Affimed: AFM24's Update Was Good, Acimtamig's Should Be Better
|
Jun 7 |
Vanda (VNDA) Surges 24.2%: Is This an Indication of Further Gains?
|
Jun 5 |
Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024
|
Jun 4 |
Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study
|
Jun 4 |
Is Affimed (AFMD) Outperforming Other Medical Stocks This Year?
|
Jun 3 |
Why Is German Biotech Affimed Stock Soaring On Monday?
|
Jun 1 |
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort
|
May 29 |
Affimed gets FDA fast track status for AFM24 for EGFR lung cancer
|
May 29 |
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer
|
May 28 |
Affimed Announces Annual General Meeting of Shareholders
|